Industry News
Biotechnology Industry News

Following Merck and Moderna’s…
Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has faltered in a reminder of the approach’s struggles as a standalone therapy.
AusperBio Therapeutics has raised…
AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis B through phase 3 testing and hopefully on to commercialization.
BioXcel Therapeutics has filed for…
BioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.
Roche has decided to pay $190…
Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fierce has learned.
Roche’s Genentech is paying…
Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with the modality. The deal is worth more than $1
September 2025 marked a low point…
September 2025 marked a low point for relations between the U.K. government and Big Pharma. Fierce reached out to the companies involved to see if they've softened their stance.
Vivace Therapeutics has…
Vivace Therapeutics has named Craig Gibbs, Ph.D., as its new president and CEO.
Osivax has licensed an influenza…
Osivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its midphase candidate complements traditional flu shots.
Flagship Pioneering’s ProFound…
Flagship Pioneering’s ProFound Therapeutics is keeping its string of high-profile partnerships going, forging a new pact with the Gates Foundation worth up to $35 million to find new drug targets for a dangerous pregnancy complication.
Leading biotechs are rethinking…
Leading biotechs are rethinking China’s role in global clinical development. Early inclusion can unlock significant value.
Just two months after Someit…
Just two months after Someit Sidhu, M.D., succeeded in pairing off his second special purpose acquisition company (SPAC) with Talawar Therapeutics, the biotech entrepreneur is back at it again.
Hansoh Pharmaceutical has given a…
Hansoh Pharmaceutical has given a bullish assessment of China’s innovative pharma sector, arguing that the industry is “fully transitioning from the ‘follower’ to the ‘frontrunner’ phase.”
Phase 2 data on Spyre…
Phase 2 data on Spyre Therapeutics’ anti-TL1A antibody SPY072 in rheumatoid arthritis have fallen short of expectations, prompting the biotech to deprioritize monotherapy development in the indication.
SK Biopharmaceuticals has…
SK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.
After announcing the “tough but…
After announcing the “tough but necessary” decision to lay off some employees last year, Frontier Medicines is looking to the future by advancing more cancer drugs into the clinic while continuing to find partners to
Having set Metsera on its journey…
Having set Metsera on its journey to a $10 billion takeover, Arch Venture Partners and Population Health Partners have powered their new startup—Sentivera—to a licensing deal worth up to $1.5 billion.
The FDA has extended its review of…
The FDA has extended its review of Capricor Therapeutics’ Duchenne muscular dystrophy drug candidate, deferring the decision to review information the biotech submitted after a negative advisory committee vote.
A new report on the health of the…
A new report on the health of the Massachusetts biotech scene has painted a mixed picture of how drug developers are faring in the Bay State.
TME Pharma’s hunt for a partner…
TME Pharma’s hunt for a partner for its brain cancer drug is closer to bearing fruit as the German biotech clings onto its hope of generating $1 billion in peak sales from the asset.
Spruce Biosciences has taken…
Spruce Biosciences has taken another step toward filing for FDA approval of its ultra-rare disease drug candidate, ticking off some of the manufacturing tasks needed to submit the long-awaited application.

